Inhibiting cyclin d polypeptides
AssigneesMayo Foundation for Medical Education and Research, University Health Network
InventorsRodger E. Tiedemann, Alexander Keith Stewart, Aaron David Schimmer, Xinliang Mao
Life of this patent
Estimating the term…
Abstract
This document involves methods and materials related to inhibiting cyclin D polypeptide activity. For example, this document provides methods and materials that can be used to (1) identify mammals or cells in need of cyclin D polypeptide inhibition and (2) administer an agent capable of inhibiting cyclin D polypeptide activity.
Claims36
A method for reducing cyclin D polypeptide activity within a cell, wherein said method comprises:
- (a) identifying a cell in need of reduced cyclin D polypeptide activity, and
- (b) administering an agent to said cell, wherein said agent is β-lapachone, dihydrogambogic acid, pristimerin, or kinetin riboside.
A method for treating a mammal having a myeloma, wherein said method comprises administering kinetin riboside and a glucocorticosteroid to said mammal.
A method for reducing the number of viable cancer cells within a mammal, wherein said method comprises:
- (a) identifying a mammal having viable cancer cells in need of reduced cyclin D polypeptide activity, and
- (b) administering an agent to said mammal under conditions wherein the number of viable cancer cells within said mammal is reduced, wherein said agent is β-lapachone, dihydrogambogic acid, pristimerin, kinetin riboside, or a combination thereof.
A method for reducing the number of viable cancer cells within a mammal, wherein said method comprises:
- (a) identifying a mammal having viable cancer cells in need of reduced cyclin D polypeptide activity, and
- (b) administering β-lapachone to said mammal under conditions wherein the number of viable cancer cells within said mammal is reduced.
A method for reducing the number of viable cancer cells within a mammal, wherein said method comprises:
- (a) identifying a mammal having viable cancer cells in need of reduced cyclin D polypeptide activity, and
- (b) administering dihydrogambogic acid to said mammal under conditions wherein the number of viable cancer cells within said mammal is reduced.
A method for reducing the number of viable cancer cells within a mammal, wherein said method comprises:
- (a) identifying a mammal having viable cancer cells in need of reduced cyclin D polypeptide activity, and
- (b) administering pristimerin to said mammal under conditions wherein the number of viable cancer cells within said mammal is reduced.
A method for reducing the number of viable cancer cells within a mammal, wherein said method comprises:
- (a) identifying a mammal having viable cancer cells in need of reduced cyclin D polypeptide activity, and
- (b) administering kinetin riboside to said mammal under conditions wherein the number of viable cancer cells within said mammal is reduced.
Dependencies are inferred from the claim text.